ArticleThe Journal of urology2016
How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Article in The Journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Trends in the Adoption of MRI Associated Biopsy for Active Surveillance Within the First Year After Localized Prostate Cancer Diagnosis: A SEER-Medicare Cohort Study.Cancer medicine · 2026Article
- Active Surveillance for Localized Prostate Cancer: A Retrospective Single-Center Study.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Determinants of Nonattendance in a Urology Outpatient Clinic: A 5-Year Retrospective Study in a Tertiary Metropolitan Hospital.ANZ journal of surgery · 2025Article
- A Payment Incentive to Improve Confirmatory Testing in Men With Prostate Cancer.JAMA network open · 2025Article
- "Watch-and-Wait" or "Lost to Follow-Up"? Adherence to Nonoperative Management of Rectal Cancer.The Journal of surgical research · 2025Article
- Using real-world, population-level data to assess the uptake of active surveillance for low-grade prostate cancer before and after the release of clinical guidelines.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer.Cancer medicine · 2025Article
- Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.Cancer · 2025Article
- Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer.Urology practice · 2024Article
- Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy.Exploration of targeted anti-tumor therapy · 2024Article
- Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study.Cancer medicine · 2024Article
- Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.JCO clinical cancer informatics · 2023Article
- Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.Prostate cancer and prostatic diseases · 2023Article
- Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.The Journal of urology · 2023Article
- Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.The Journal of urology · 2022Article
- Magnetic Resonance Imaging-guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies.European urology open science · 2022Article
- Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study.Prostate cancer and prostatic diseases · 2022Article
- Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.Prostate cancer and prostatic diseases · 2022Article
- Understanding Active Surveillance for Prostate Cancer.JCO oncology practice · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
purposeWhile major prostate cancer active surveillance programs recommend repeat testing such as prostate specific antigen and prostate biopsy, to our knowledge compliance with such testing is unknown. We determined whether men in the community receive the same intensity of active surveillance testing as in prospective active surveillance protocols. MATERIALS AND
methodsWe performed a retrospective cohort study of men 66 years old or older in the SEER (Surveillance, Epidemiology and End Results)-Medicare database. These men were diagnosed with prostate cancer from 2001 to 2009, did not receive curative therapy in the year after diagnosis and underwent 1 or more post-diagnosis prostate biopsies. We used multivariable adjusted Poisson regression to determine the association of the frequency of active surveillance testing with patient demographics and clinical features. In 1,349 men with 5 years of followup we determined the proportion who underwent testing as intense as that recommended by the Sunnybrook Health Sciences Centre and PRIAS (Prostate Cancer Research International Active Surveillance) programs, including 14 or more PSA tests and 2 or more biopsies, and The Johns Hopkins program, including 10 or more prostate specific antigen tests and 4 or more biopsies.
resultsAmong 5,192 patients undergoing active surveillance greater than 80% had 1 or more prostate specific antigen tests per year but fewer than 13% underwent biopsy beyond the first 2 years. Magnetic resonance imaging was rarely done during the study period. On multivariable analysis recent diagnosis and higher income were associated with a higher frequency of surveillance biopsy while older age and greater comorbidity were associated with fewer biopsies. African American men underwent fewer prostate specific antigen tests but a similar number of biopsies. During 5 years of active surveillance only 11.1% and 5.0% of patients met the testing standards of the Sunnybrook/PRIAS and The Johns Hopkins programs, respectively.
conclusionsIn the community few elderly men receive the intensity of active surveillance testing recommended in major prospective active surveillance programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.